Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States.
Journal Information
Full Title: World J Gastrointest Oncol
Abbreviation: World J Gastrointest Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict-of-interest statement: Dr.Li reports personal fees and other from AstraZeneca, other from Brooklyn ImmunoTherapeutics, personal fees from Adagene, personal fees from Coherus, personal fees from Delcath, personal fees from Eisai, personal fees from Exelixis, personal fees from Genentech, personal fees from Ipsen Biopharmaceuticals, personal fees from Merck, personal fees from Servier, personal fees from Sumitomo Pharma, and personal fees from TerSera Therapeutics, outside the submitted work."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025